Multiple HLA-A2402 restricted epitope peptide vaccine (University of Tokyo/OncoTherapy Science)

N/A

Report date: 2024/03/01 20:05:21

Base Information

Drug NameMultiple HLA-A2402 restricted epitope peptide vaccine (University of Tokyo/OncoTherapy Science)
Drug Alias NameURLC10 + TTK + VEGFR1 + VEGFR2-derived HLA-A2402 restricted epitope peptide multiple vaccine (NSCLC)Multiple peptide vaccine (metastatic NSCLC)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionVascular endothelial growth factor receptor 2 modulatorsDual specificity protein kinase TTK modulatorsVascular endothelial growth factor receptor 1 modulators
TargetsVascular endothelial growth factor receptor 1Vascular endothelial growth factor receptor 2Dual specificity protein kinase TTK
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncotherapy Science, IncUniversity Of Tokyo
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of TokyoShiga University
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A